Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

dermix mexico - dapsona - dapsona....100 mg.

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Philippines - English - FDA (Food And Drug Administration)

organon (philippines), incorporated - ezetimibe , rosuvastatin (as calcium) - film-coated tablet - 10 mg/5 mg

Philippines - English - FDA (Food And Drug Administration)

organon (philippines), incorporated - ezetimibe , rosuvastatin (as calcium) - film-coated tablet - 10 mg/10 mg

Philippines - English - FDA (Food And Drug Administration)

organon (philippines), incorporated - ezetimibe , rosuvastatin (as calcium) - film-coated tablet - 10 mg/20 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; silicon dioxide; microcrystalline cellulose - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 25 mg - tablet, uncoated - excipient ingredients: silicon dioxide; magnesium stearate; microcrystalline cellulose; maize starch - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.

Canada - English - Health Canada

laboratoire riva inc. - dapsone - tablet - 100mg - dapsone 100mg - miscellaneous antimycobacterials

United States - English - NLM (National Library of Medicine)

pacific pharma, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 50 mg in 1 g - dapsone gel, 5%, is indicated for the topical treatment of acne vulgaris. none. risk summary there are no available data on dapsone gel, 5% in pregnant women to inform a drug-associated risk for adverse developmental outcomes. in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 250 times the systemic exposure at the maximum recommended human dose (mrhd) of dapsone gel, 5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 400 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data] . the estimated background risks of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4%

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 50 mg in 1 g - dapsone gel, 5%, is indicated for the topical treatment of acne vulgaris. none. risk summary there are no available data on dapsone gel, 5%, use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 250 times the systemic exposure at the maximum recommended human dose (mrhd) of dapsone gel, 5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 400 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data] . the estimated background risks of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is